Benign Prostatic Hyperplasia

“For some men, it's very important to make sure that they have an antegrade ejaculation and this is a treatment modality that we're able to offer them,” says Andrew Higgins, MD.

“What's novel about the iTind system is [that] it's one of the first treatments that [can] be deployed through a flexible cystoscope, as well as the fact that there is no permanent energy or permanent foreign body that's left within the prosthetic urethra,” says Bilal Chughtai, MD.

In this interview, Dean Elterman, MD, discusses Rezum and Aquablation abstracts he presented at the 2021 AUA Annual Meeting and provides his overall perspective on the treatment of BPH.

Get ready for the 2021 AUA annual meeting with this preview of non-malignant topics.

"Patients with BPH appear to have a potential protective factor against prostate cancer," said Kiran Nandalur, MD.

The research also showed that the decision aid was well-received by patients as both satisfaction of men who used the tool and their willingness to recommend their physician were very high.

A logistic regression analysis controlling for other major comorbidities, patient age, insurance status, and type of medical therapy found that Black patients were almost 40% less likely than White patients to undergo surgery for BPH.

“Urologists tend to be early adopters of new technology. That said, how fast adoption of prostatic urethral lift has been in the urologic community was really impressive,” says Jonathan Shoag, MD.

“This study suggests that there is little difference in erectile dysfunction between the various treatments over 60-month follow-up,” says Peter Gilling, MD.

Plaintiff alleges injury occurred during insertion of Foley catheter.

“Clinicians should considerer these data when prescribing 5-ARIs to patients,” said Dr. Antonio Franco.

"Depending on the age of the surgeon, one may be surprised to hear that it was common to perform a vasectomy routinely on patients undergoing a TURP procedure," write Jonathan Rubenstein, MD, and Mark Painter.

“[These findings] provide intriguing insights into the etiology and genetic components of BPH,” said study author Joel T. Funk, MD.

A recently published study showed an increased risk of cardiac failure in men with BPH and exposure to 5-alpha reductase inhibitors and/or α-blockers.

MRI-guided transurethral ultrasound ablation (TULSA) demonstrated efficacy and safety as a treatment for patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

The UroLift System is a noninvasive treatment for patients with BPH that relieves prostate obstruction by lifting and holding the prostate tissue that is blocking the urethra.

Nearly half of the surveyed men reported that urinary symptoms led them to avoid events or activities they enjoy.

The primary outcome measure of the phase 3 ATHLETE study is the noninferiority of aquablation versus HoLEP in alleviating lower urinary tract symptoms related to benign prostatic obstruction.

In this interview, Alexis E. Te, MD, discusses the evolution of LUTS treatment, what primary care providers should include in their evaluation when seeing a patient with LUTS, and how he selects treatments for patients with BPH.

"Retreatment is the new buzz word and is very controversial, as parameters keep changing," writes Gopal H. Badlani, MD.

Tadfin is a once-daily capsule that combines 5 mg of tadalafil (Cialis) with 5 mg of finasteride (Proscar).

The test can help clinician determine whether a second procedure would be of benefit to a patient.

There were also no reports of sexual dysfunction related to device or procedure and no reported cases of sustained de novo erectile dysfunction at 5 years.

The Optilume drug-coated balloon catheter system is used to treat patients with lower urinary tract symptoms related to benign prostatic hyperplasia.

The study encompassed the prostatic urethral lift (UroLift), water vapor thermal therapy (Rezum), and temporary implantable nitinol device (iTIND).